Identification and Characterization of Novel Pneumococcal Choline Binding Protein, CBPG, and Diagnostic and Therapeutic Uses Thereof (SJ-98-0028)



Technology Name
(St. Jude Reference #)
Identification and Characterization of Novel Pneumococcal Choline Binding Protein, CBPG, and Diagnostic and Therapeutic Uses Thereof (SJ-98-0028)
Description This invention describes the identification of a pneumococcal choline binding protein, CbpG, which can be used as an immunogenic polypeptide to develop a vaccine against Strep. pneumoniae. Alternatively, this polypeptide could be used as a therapeutic agent to block adhesion of the bacteria to the lining of the respiratory tract in patients already infected with the bacterium.
Keywords CbpG, choline binding proteins, antibiotic-resistant bacteria, vaccine, pneumonia, Streptococcus pneumoniae
Granted Patents or Published Applications U.S. Patent No. 6,495,139
Related Scientific References Tuomanen, et al., “Pathogenesis of pneumococcao infection”,  New Eng Jour Med 322:1280-1284 (1995);
Cundell and Tuomanen, “Receptor specificity of adherence of Streptococcus pneumoniae to human-typeII pneumocytes and vascular endothelial cells in  vitro” Mircob Pathog 17:361-374 (1994);
Hoepelman and Tuomanen, “Consequences of microbial attachment: directing host cell functions with adhesions” Infect Immun 60:1729-33 (1992).
Licensing Opportunities We are currently seeking licensing opportunities in all fields for the development of this technology.

 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

 

Last update: September 2008